Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free EVFM Stock Alerts

Evofem Biosciences (EVFM) Competitors

Evofem Biosciences logo
$0.0075 0.00 (-5.06%)
As of 11:25 AM Eastern
Compare

EVFM vs. REVB, APM, UPC, RDHL, and XRTX

Should you buy Evofem Biosciences stock or one of its competitors? Evofem Biosciences's main competitors and comparable companies include Revelation Biosciences (REVB), Aptorum Group (APM), Universe Pharmaceuticals (UPC), Redhill Biopharma (RDHL), and XORTX Therapeutics (XRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Evofem Biosciences compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Revelation Biosciences has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -100.19% -82.72%
Evofem Biosciences -46.42%-91.97%-61.93%

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Evofem Biosciences has higher revenue and earnings than Revelation Biosciences. Evofem Biosciences is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$12.31N/A
Evofem Biosciences$11.39M0.09$52.98M-$0.07N/A

Revelation Biosciences has a beta of -0.15, suggesting that its share price is 115% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market.

In the previous week, Revelation Biosciences had 6 more articles in the media than Evofem Biosciences. MarketBeat recorded 6 mentions for Revelation Biosciences and 0 mentions for Evofem Biosciences. Revelation Biosciences' average media sentiment score of 0.75 beat Evofem Biosciences' score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Revelation Biosciences Positive
Evofem Biosciences Neutral

Summary

Revelation Biosciences beats Evofem Biosciences on 7 of the 12 factors compared between the two stocks.

How does Evofem Biosciences compare to Aptorum Group?

Aptorum Group (NASDAQ:APM) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aptorum Group's average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company Overall Sentiment
Aptorum Group Neutral
Evofem Biosciences Neutral

Evofem Biosciences has higher revenue and earnings than Aptorum Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptorum Group$430K9.86-$1.36MN/AN/A
Evofem Biosciences$11.39M0.09$52.98M-$0.07N/A

Aptorum Group has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Aptorum Group's return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptorum GroupN/A N/A N/A
Evofem Biosciences -46.42%-91.97%-61.93%

Aptorum Group has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptorum Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Aptorum Group beats Evofem Biosciences on 8 of the 10 factors compared between the two stocks.

How does Evofem Biosciences compare to Universe Pharmaceuticals?

Evofem Biosciences (NASDAQ:EVFM) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Universe Pharmaceuticals has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Universe Pharmaceuticals' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
Universe Pharmaceuticals N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Evofem Biosciences has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

In the previous week, Universe Pharmaceuticals had 2 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 0 mentions for Evofem Biosciences. Universe Pharmaceuticals' average media sentiment score of 1.43 beat Evofem Biosciences' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Evofem Biosciences Neutral
Universe Pharmaceuticals Positive

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evofem Biosciences has higher earnings, but lower revenue than Universe Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.09$52.98M-$0.07N/A
Universe Pharmaceuticals$17.86M1.59-$3.67MN/AN/A

Summary

Universe Pharmaceuticals beats Evofem Biosciences on 10 of the 12 factors compared between the two stocks.

How does Evofem Biosciences compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Redhill Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Evofem Biosciences has higher revenue and earnings than Redhill Biopharma. Evofem Biosciences is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redhill Biopharma$290K12.12-$430K$900.000.00
Evofem Biosciences$11.39M0.09$52.98M-$0.07N/A

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Redhill Biopharma has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Redhill Biopharma's return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Redhill BiopharmaN/A N/A N/A
Evofem Biosciences -46.42%-91.97%-61.93%

Redhill Biopharma has a beta of 5, meaning that its share price is 400% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.32, meaning that its share price is 232% less volatile than the broader market.

In the previous week, Redhill Biopharma had 3 more articles in the media than Evofem Biosciences. MarketBeat recorded 3 mentions for Redhill Biopharma and 0 mentions for Evofem Biosciences. Redhill Biopharma's average media sentiment score of 0.37 beat Evofem Biosciences' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Redhill Biopharma Neutral
Evofem Biosciences Neutral

Summary

Redhill Biopharma beats Evofem Biosciences on 11 of the 13 factors compared between the two stocks.

How does Evofem Biosciences compare to XORTX Therapeutics?

Evofem Biosciences (NASDAQ:EVFM) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Evofem Biosciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Evofem Biosciences has higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.09$52.98M-$0.07N/A
XORTX TherapeuticsN/AN/A-$2.66M-$2.63N/A

XORTX Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
XORTX Therapeutics N/A -150.01%-106.53%

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, XORTX Therapeutics had 2 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for XORTX Therapeutics and 0 mentions for Evofem Biosciences. XORTX Therapeutics' average media sentiment score of 0.93 beat Evofem Biosciences' score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Evofem Biosciences Neutral
XORTX Therapeutics Positive

Summary

XORTX Therapeutics beats Evofem Biosciences on 7 of the 12 factors compared between the two stocks.

Get Evofem Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVFM vs. The Competition

Export
MetricEvofem BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$994K$11.73B$6.98B$13.04B
Dividend YieldN/A2.70%2.58%10.72%
P/E Ratio-0.01781.47269.8625.30
Price / Sales0.09750.79601.81101.06
Price / CashN/A67.4570.5350.75
Price / Book0.0010.8113.086.33
Net Income$52.98M$2.77B$3.45B$347.70M
7 Day PerformanceN/A0.17%1.12%1.07%
1 Month PerformanceN/A0.35%1.79%1.03%
1 Year PerformanceN/A161.52%67.69%20.77%

Evofem Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVFM
Evofem Biosciences
N/A$0.01
-5.1%		N/A-15.1%$994K$11.39MN/A120
REVB
Revelation Biosciences
0.7437 of 5 stars		$1.15
+1.8%		N/A-89.0%$4.42MN/AN/A10
APM
Aptorum Group
0.302 of 5 stars		$0.67
-4.6%		N/A-95.3%$4.24M$430KN/A30
UPC
Universe Pharmaceuticals
1.367 of 5 stars		$6.16
-12.6%		N/A+33.4%$3.97M$17.86MN/A220
RDHL
Redhill Biopharma
1.1176 of 5 stars		$0.63
-2.3%		N/A-57.2%$3.94M$290K0.00210

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVFM) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Your Opinion of Trump Won't Matter After November 27
Forensic accountant Joel Litman, who called the 2008 crisis and the 2020 COVID bottom, says a $10 trillion shi...
Altimetry | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel